Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Upjohn
|
| gptkbp:activities |
calcium channel modulator
|
| gptkbp:approves |
gptkb:2004
gptkb:psychologist fibromyalgia generalized anxiety disorder neuropathic pain |
| gptkbp:brand |
gptkb:Lyrica
|
| gptkbp:clinical_trial |
Phase III
pain management anxiety treatment seizure control |
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to pregabalin |
| gptkbp:developed_by |
gptkb:Pfizer
|
| gptkbp:dosage_form |
oral
|
| gptkbp:formulation |
gptkb:beer
oral solution |
| https://www.w3.org/2000/01/rdf-schema#label |
Lyrica
|
| gptkbp:indication |
chronic pain
seizures anxiety disorders |
| gptkbp:ingredients |
pregabalin
|
| gptkbp:interacts_with |
gptkb:beer
CNS depressants opioids |
| gptkbp:invention |
gptkb:2018
|
| gptkbp:is_available_on |
generic version
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:Lyrica
over 100 countries |
| gptkbp:origin |
gptkb:United_States
|
| gptkbp:provides_information_on |
recommended for neuropathic pain
recommended for fibromyalgia recommended for seizure disorders |
| gptkbp:research_focus |
anxiety disorders
neurological disorders chronic pain management epilepsy treatment |
| gptkbp:sales |
billions annually
|
| gptkbp:scholarships |
avoid alcohol
monitor for mood changes do not discontinue abruptly report any unusual side effects |
| gptkbp:side_effect |
dizziness
drowsiness dry mouth weight gain blurred vision |
| gptkbp:storage |
room temperature
protected from light protected from moisture |